President, Utah Lipid Center; Director, Atherometabolic Research, Utah Foundation for Biomedical Research
Endocrinology
Dr. Eliot A. Brinton, MD
|
|
Give Review
Eliot Brinton is an expert in the field of Endocrinology. He researched medicine at University of Utah School of Medicine. Eliot A. Brinton is also a published doctor. He has 67 paper published. The most recent paper is: Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without ...
Publications
- Hyperlipoproteinemia Type 3: the forgotten phenoType.
- Letter by Jones et al regarding article, "Elevated remnant Cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipo...
- Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study.
- The KEEPS-Cognitive and Affective Study: Baseline Associations between Vascular Risk Factors and Cognition.
- Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in P...
- Measurement of LDL-C after treatment With the CETP inhibitor anacetrapib.
- Self-reported menopausal symptoms, coronary artery calcification, and carotid intima-media thickness in recently menopausal women screened for the Kronos early estroge...
- Search and rescue for hypotheses surviving AIM-High, the niacin therapy earthquake: Still problematic after the primary publication.
- Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen P...
- Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes.
- Menopausal hormone therapy and risk for cardiovascular disease in the WHI trial.
- Hot flashes and hormone use: harbingers of heart disease?
- Health outcomes of gastric bypass patients compared to nonsurgical, nonintervened severely obese.
- Can menopausal hormone therapy prevent coronary heart disease?
- Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
- Postmenopausal hormone therapy: new questions and the case for new clinical trials.
- Controversies in dyslipidemias: atheroprevention in Diabetes and insulin resistance.
- Women, hormones, and clinical trials: a beginning, not an end.
- Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
- Plasma triglycerides and Type III hyperlipidemia are independently associated with premature familial coronary artery disease.
- Is the WHI relevant to HRT started in the perimenopause?
- Triglyceride-rich lipoprotein remnant levels and metabolism: time to adopt these orphan risk factors?
- Assessing low levels of High-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update.
- Estrogen Receptor 1 variants and coronary artery disease: shedding light into a murky pool.
- Lipid abnormalities in the metabolic syndrome.
- Extended-release niacin/laropiprant significantly improves lipid levels in type 2 Diabetes mellitus irrespective of baseline glycemic control.
- Characterization of vascular disease risk in postmenopausal women and its association With cognitive performance.
- Effects of angiotensin II Type 1 receptor blockade on beta-cell function in humans.
- The Women''s Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition.
- Assessing and addressing risk of cardiovascular disease in perimenopausal and early postmenopausal women.
- Lp A-I and niacin: new views of an antiatherogenic duo.
- Newer HMG-CoA reductase inhibitor (statin) therapies.
- Alcohol consumption raises HDL Cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II.
- The role of fibric acid derivatives in the secondary prevention of coronary heart disease.
- Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with Diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. A...
- Postmenopausal hormone replacement improves proteinuria and impaired creatinine clearance in type 2 Diabetes mellitus and hypertension.
- Cardiovascular effects of droloxifene, a new selective estrogen Receptor modulator, in healthy postmenopausal women.
- Very small apolipoprotein A-I-containing particles from human plasma: isolation and quantification by High-performance size-exclusion chromatography.
- Hormone replacement therapy reduces mean 24-hour blood pressure and its variability in postmenopausal women With treated hypertension.
- Metabolic and genetic determinants of HDL metabolism and hepatic lipase activity in normoLipidemic females.
- Amputation prevention by vascular surgery and podiatry collaboration in High-risk diabetic and nondiabetic patients. The Operation Desert Foot experience.
- Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity Without ...
- Metabolic determinants of low HDL-C levels.
- Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely With estimates of HDL particle size. Effects of gender, hep...
- Regulation of High density lipoprotein receptor activity in cultured human skin fibroblasts and human arterial smooth muscle cells.
- Regulation of high density lipoprotein binding activity of aortic endothelial cells by treatment With acetylated low density lipoprotein.
- Binding of High density lipoprotein to cultured fibroblasts after chemical alteration of apoprotein amino acid residues.
- The effect of variations in lipid composition of high-density lipoprotein on its interaction With receptors on human fibroblasts.
- Heritable allele-specific differences in amounts of apoB and low-density lipoproteins in plasma.
- Elevated high density lipoprotein cholesterol levels correlate With decreased apolipoprotein A-I and A-II fractional catabolic rate in women.
- A low-fat diet decreases High density lipoprotein (HDL) cholesterol levels by decreasing HDL apolipoprotein transport rates.
- Increased apo A-I and apo A-II fractional catabolic rate in patients With low high density lipoprotein-cholesterol levels With or Without hypertriglyceridemia.
- Hypertriglyceridemia in patients With psoriasis treated With cyclosporine.
- Polymorphism in the human apolipoprotein A-I gene promoter region. Association of the minor allele With decreased production rate in vivo and promoter activity in vitro.
- Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS).
- KEEPS: The Kronos Early Estrogen Prevention Study.
- Heterozygosity for ABCA1 gene Mutations: effects on enzymes, apolipoproteins and lipoprotein particle size.
- Management of diabetic dysLipidemia: doing the right thing.
- Novel pathways for glycaemic control in type 2 Diabetes: focus on bile acid modulation.
- Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition With AnacEtrapib.
- Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal women.
- Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study.
- Effects of ethanol intake on lipoproteins and atherosclerosis.
- Safety of anacetrapib in patients With or at high risk for coronary heart disease.
- Niacin extended-release therapy in phase III clinical trials is associated With relatively low rates of drug discontinuation due to flushing and treatment-related adve...
- The importance of non-HDL Cholesterol reporting in lipid management.
Schools
University Of Utah School Of Medicine
Duke University Hospital
University of Washington
Stanford University
University of Utah
Procedures Preformed
- Cholesterol Management
- Lipid Management
- Therapeutic Apheresis
Conditions Treated
- Diabetes Type 2
- Diabetes With Renal Manifestations
- Familial Combined HyperLipidemia
- Familial HyperCholesterolemia
- View All
Doctors Specialties
- Clinical Lipidology
- Endocrinology
Accepted Insurances
Education
-
University of Washington -
Duke University Hospital -
University of Utah School of Medicine
Helpful Reviews
Similar Doctors
|
Dr. Leanne Swenson, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gitana Staskus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. A W. Meikle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul A. Miner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amnon Schlegel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Alireza Falahati-Nini, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Bruce R. Brady, MD
This Doctor is OpenDoctor Recommended.
|